<DOC>
	<DOCNO>NCT02365454</DOCNO>
	<brief_summary>A multicenter , prospective , open-label , non-randomized , interventional clinical study , sponsor Endospan Ltd . Patients followed-up five year .</brief_summary>
	<brief_title>NEXUS™ Aortic Arch Stent Graft System First In Man Study</brief_title>
	<detailed_description>The purpose study evaluate safety performance Nexus™ Aortic Arch Stent Graft System endovascular treatment thoracic aortic pathology require land Aortic Arch ( zone 0 , zone 1 , zone 2 ) . The Nexus™ Aortic Arch Stent Graft System indicate endovascular treatment thoracic aortic pathology involve aortic arch ( aneurisms dissection ) . The Nexus™ intend exclude lesion blood circulation patient diagnose thoracic aortic pathology appropriate anatomy accommodate Nexus™ system endovascular procedure . The primary objective study evaluate safety performance Nexus™ Aortic Arch Aneurysm Stent Graft System .</detailed_description>
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm , Thoracic</mesh_term>
	<criteria>Male female age ≥ 18 . Any Thoracic Aorta pathology require land Aortic Arch ( zone 0 , zone 1 , zone2 ) , e.g . aneurysm , dissection , false/Pseudo aneurysm . In patient thoracic aneurysm : dilatation aortic arch large 5.5cm diameter , symptomatic aneurysm aortic arch , aortic diameter growth rate &gt; 5mm per 6 month Patient consider appropriate candidate elective surgery , evaluate Physical Status Classification System I , II III ( American Society Anesthesiologists ) . Femoral artery diameter document CTA MRA allow endovascular access diseased site 2022Fr delivery catheter . Access vessel morphology suitable endovascular repair term tortuosity , calcification angulation , document CTA , MRA . Access vessel ( femoral/iliac ) diameter &gt; 7 mm Ascending Aorta land zone length &gt; 30 mm Brachial/Axial Artery diameter &gt; 3 mm Patient understand voluntarily willing participate evidence personally sign Informed Consent document , willingness comply followup schedule Female childbearing potential Life expectancy less 1 year Any medical condition , accord investigator 's decision , might expose patient increase risk investigational device procedure . Acutely rupture instable aneurysm acute vascular injury due trauma infected penetrate ulcer aorta . Patient increase risk aneurysm rupture procedure . Patient whose arterial access site anticipated accommodate access Nexus™ Delivery System , due size , tortuosity hostile groin ( scar , obesity , previous fail puncture ) Patients severe atherosclerosis intraluminal thrombus aorta BCT Patient suffer unstable angina NYHA classification III IV and/or ASA classification IV . Patient myocardial infarction ( MI ) cerebral vascular accident ( CVA ) within 3 month prior plan implantation Patient know hypersensitivity contraindication anticoagulant , antiplatelets , contrast medium , amenable pretreatment . Patient contraindication undergo angiography Patient know sensitivity allergy device material Nitinol polyester Clinical condition severely inhibit xray visualization Aorta . Connective tissue disease ( e.g. , Marfan 's Ehler'sDanlos syndrome ) Patient history bleed diathesis coagulopathy may limit use dual antiplatelet anticoagulant therapy decision investigator Patient active systemic infection time procedure document pain , fever , drainage , positive culture and/or leukocytosis ( WBC &gt; 11,000 mm3 ) . Patients condition threatens infect stent graft . Acute renal failure ; chronic renal failure ( exclude dialysis ) ; Creatinine &gt; 2.00 mg/dl &gt; 182 umol/L Patient underwent major surgery interventional procedure last three month . Any medical , social , psychological issue opinion investigator preclude receive treatment , procedure evaluation pre post treatment . Active participation another clinical trial reasonable conflict NexusTM study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>TAA</keyword>
</DOC>